Best of ASCO - 2014 Annual Meeting

 

Welcome

Vaccines

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris

2523

A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.

ANA Maria Arance Fernandez

2641

A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.

Ana Blazquez

e14307

An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.

Mark R. Middleton

TPS2671

Analysis of Chinese acral and mucosal melanoma patient genomic and neoantigen profiles in cancer vaccine development: A pilot study.

Xianling Guo

e14300

Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity.

Klaus Karl Orlinger

e14297

Effect of subcutaneous multipeptide active antigen-specific immunotherapy at lymph nodes and tumor sites on clinical outcomes in progressive tumors.

Juan Pablo Marquez-Manriquez

2636

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1).

Jooeun Bae

e14302

Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.

Luis Teixeira

2642

Human model to predict the outcome of cancer vaccine clinical trials.

Orsolya Lőrincz

e14298

Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.

Gal Cafri

2643

Induction of antigen specific CD8+ T cell infiltration by a novel neoadjuvant vaccine containing HSP70 and GPC3 peptides plus soluble LAG-3 and Poly-IC:LC: Interim results of a Phase I study.

Yukio Tokumitsu

e14306

Live-attenuated LCMV-based vector for active immunotherapy of HPV16+ cancer.

Sarah Schmidt

e14303

Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.

Julie Marie Collins

2640

Prediction the clinical outcomes of cancer patients after peptide vaccination.

Eniko Rita Toke

e14295

Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).

Hoyoung M. Maeng

2639

Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.

Robert O. Dillman

2637

Systematic assessment of LCMV based vaccine vectors expressing melanocyte differentiation antigens in human in vitro assays and in mouse melanoma models.

Lukas Flatz

e14299